Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 6Gastrointestinal 2Breast 2

Conditions

Weight Loss 1Sarcopenia 1Postoperative Complications 1Obesity 1Muscle Weakness 1Intermittent Fasting 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Caloric Restriction × Gastrointestinal × Clear all
NCT05114798 2026-05-22

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

University of Illinois at Chicago

Phase NA Active not recruiting
193 enrolled
GastrointestinalOther

Intermittent Fasting, Obesity, Colorectal Neoplasms, Weight Loss

NCT03676478 2025-12-10

EFECTS

University Hospital, Gasthuisberg

Phase NA Terminated
239 enrolled
Gastrointestinal

Esophageal Neoplasms, Postoperative Complications, Muscle Weakness, Sarcopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡